Involvement of osteopontin in the matrix-degrading and proangiogenic changes mediated by nicotine in pancreatic cancer cells.
BACKGROUND
Substantial evidence indicates that exposure to cigarette smoke is associated with an elevated risk of pancreatic ductal adenocarcinoma (PDA). However, the mechanisms underlying the effects of nicotine on the development or progression of PDA remain to be investigated. Previously, we showed that nicotine promotes the expression of osteopontin c (OPNc), an isoform of OPN protein that confers on cancer cells a migratory phenotype. In this study, we explored the potential prometastatic role of nicotine in PDA through studying its effect on the expression of matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) and evaluated the role of OPN in mediating these effects.


METHODS
MMP-9 and VEGF mRNA and protein were analyzed in PDA cells treated with or without nicotine (3-300 nM). Transient transfection and luciferase-labeled promoter studies evaluated the effects of OPNc and OPN protein on the transcription and translation of MMP-9 and VEGF. Real-time PCR and immunohistochemistry were used to analyze the mRNA expression levels and localization of OPN, MMP-9, and VEGF proteins in matched invasive human PDA and surrounding nonmalignant tissues.


CONCLUSIONS
Nicotine significantly enhanced the expression of MMP-9 and VEGF mRNA and protein in PDA cells. Blocking OPN with siRNA or OPN antibody prevented the nicotine-mediated increase of both MMP-9 and VEGF. Transient transfection of OPNc gene in PDA cells or their treatment with recombinant OPN protein significantly (p < 0.05) increased MMP-9 and VEGF mRNA expression levels and induced their promoter activities. In invasive PDA lesions, MMP-9 mRNA levels were significantly (p < 0.005) higher in smokers vs. nonsmokers. VEGF protein co-localized with MMP-9 and OPN in the malignant ducts and correlated well with their higher levels in invasive PDA lesions.


CONCLUSIONS
Our data show for the first time that cigarette smoking and nicotine may contribute to PDA metastasis through inducing MMP-9 and VEGF and suggest that OPN plays a central role in mediating these effects. The presence of OPN as a downstream effector of nicotine that is capable of mediating its prometastatic effects in PDA cells is novel and could provide a unique therapeutic target to control pancreatic cancer aggressiveness, especially in the cigarette-smoking population.
Lazar
Melissa
M
Department of Surgery, Jefferson Pancreatic, Biliary and Related Cancer Center, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA.
Sullivan
Jennifer
J
Chipitsyna
Galina
G
Gong
Qiaoke
Q
Ng
Chee Y
CY
Salem
Ahmed F
AF
Aziz
Tamer
T
Witkiewicz
Agnes
A
Denhardt
David T
DT
Yeo
Charles J
CJ
Arafat
Hwyda A
HA
D002273:Carcinogens / Q000494:pharmacology*; D021441:Carcinoma, Pancreatic Ductal / Q000503:physiopathology*; D045744:Cell Line, Tumor; D005109:Extracellular Matrix / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis; D009389:Neovascularization, Pathologic / Q000503:physiopathology; D009538:Nicotine / Q000494:pharmacology*; D053495:Osteopontin / Q000378:metabolism / Q000502:physiology*; D010190:Pancreatic Neoplasms / Q000503:physiopathology*; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis
D002273:Carcinogens; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D053495:Osteopontin; D009538:Nicotine; D020780:Matrix Metalloproteinase 9
Dig Dis. 2002;20(1):32-7
12145418
Clin Exp Metastasis. 1998 Aug;16(6):501-12
9872598
J Clin Gastroenterol. 1987 Apr;9(2):175-9
3571892
Cancer Chemother Pharmacol. 1999;43 Suppl:S42-51
10357558
N Engl J Med. 2008 May 8;358(19):2039-49
18463380
Pancreas. 2009 Aug;38(6):613-8
19629003
Cancer Res. 2008 Jan 1;68(1):152-61
18172307
Pharmacol Rev. 2005 Mar;57(1):79-115
15734728
Oncogene. 2007 Sep 27;26(44):6361-71
17452979
J Natl Cancer Inst. 1994 Oct 19;86(20):1510-6
7932805
Oncogene. 2009 Sep 24;28(38):3412-22
19597469
Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):197-209
16549324
Nature. 1980 Mar 6;284(5751):67-8
6243750
Mol Cancer Res. 2006 Nov;4(11):803-10
17077165
Cancer Res. 1995 Sep 15;55(18):3964-8
7664263
BMC Cancer. 2008 Aug 16;8:241
18706098
Int J Cancer. 2002 Feb 1;97(4):432-8
11802203
Int J Cancer. 2008 Feb 15;122(4):889-97
17960616
Cancer Lett. 2010 Sep 1;295(1):27-37
20207476
J Cell Sci. 2004 Apr 1;117(Pt 9):1847-57
15075244
Nat Med. 1995 Jan;1(1):27-31
7584949
Antioxid Redox Signal. 2005 Sep-Oct;7(9-10):1275-84
16115033
Ups J Med Sci. 2008;113(1):57-64
18521799
Pancreas. 2010 Jul;39(5):595-603
20118820
J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70
9293916
Ann Med. 1999 Feb;31(1):34-45
10219712
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Int J Cancer. 1990 May 15;45(5):816-20
2335385
J Cell Mol Med. 2005 Oct-Dec;9(4):777-94
16364190
World J Surg. 2005 Mar;29(3):344-53
15696395
J Clin Invest. 2001 May;107(9):1055-61
11342566
Clin Cancer Res. 1996 Oct;2(10):1679-84
9816116
Chem Biol. 1996 Nov;3(11):895-904
8939708
Surgery. 2009 Aug;146(2):232-40
19628079
Int J Cancer. 2009 Jul 15;125(2):276-85
19358273